Articles tagged with Muscular Dystrophy
Researchers have developed a new CRISPR delivery system, CRISPR-Gold, that can repair the mutation causing Duchenne muscular dystrophy. The system achieves an 18-times-higher correction rate and improves muscle strength and agility in mice.
A new study suggests that enhancing breathing via the brain may limit respiratory muscle dysfunction in Duchenne muscular dystrophy patients. Researchers found that the brain compensates for respiratory muscle weakness by increasing diaphragm activation in mice with dystrophin deficiency.
Scientists have successfully replicated facioscapulohumeral muscular dystrophy (FSH) in mice by inserting the DUX4 gene into skeletal muscle cells. This new animal model holds great promise for developing therapies for FSH, a disease affecting an estimated 38,000 Americans. The study also reveals a previously unknown mechanism of muscl...
A new method reveals abnormally shortened telomeres in DMD patients' muscle stem cells, leading to early loss of regeneration capacity and disease progression. The finding suggests gene therapy and treatments targeting telomere length could slow or stop the disease.
A new technique developed at McGill University has made it possible to study the behavior of individual sarcomeres in muscles. The researchers found that neighboring sarcomeres adjust to the activation of one single sarcomere, leading to a cooperative mechanism that is crucial for understanding muscle contraction.
Researchers developed a gene therapy using microdystrophin to treat Duchenne muscular dystrophy in dogs. The treatment restored muscle function and stabilized clinical symptoms for over 2 years. This breakthrough could lead to a new treatment for children with the disease.
Researchers have designed two proteins that stabilize the cell scaffolding, restoring muscle structure and function in animal models of congenital muscular dystrophy. The study demonstrates significant improvements in muscle force, body weight, and lifespan, providing a potential gene therapy treatment for this rare disease.
A new Northwestern Medicine study found that weekly glucocorticoid steroid doses, such as prednisone, promote muscle repair and recovery in muscle injuries. The study showed that daily doses cause muscle wasting, but weekly doses stimulate the production of annexins and KLF15 proteins, leading to improved muscle performance.
Researchers at UT Southwestern Medical Center successfully corrected Duchenne muscular dystrophy using the gene-editing enzyme CRISPR-Cpf1. The treatment restored production of the missing dystrophin protein, providing a promising new tool for treating this progressive disease.
Duchenne muscular dystrophy affects 1 in 3,500 boys, stealing their ability to walk by age 12 and typically killing them by mid-20s. Researchers at UVA will use a multi-scale computer model to understand how muscle damage and inflammation drive the disease.
Researchers at UC Riverside have developed a new method to measure nonsense-mediated RNA decay (NMD) efficiency in real-time, allowing for the identification of molecules that regulate this pathway. This breakthrough has the potential to lead to the development of targeted treatments for diseases such as ALS and muscular dystrophy.
Research suggests that supplementing mice with quercetin improves biomedical outcomes, providing anti-inflammatory and antioxidant effects. The study also found that quercetin-fed mice were more active than control groups, which could be beneficial for Duchenne Muscular Dystrophy patients.
Researchers from GW University and St. George's University of London discovered a mutation in the INPP5K gene linked to short stature, muscle weakness, intellectual disability, and cataracts. This finding suggests a new type of congenital muscular dystrophy, with potential for targeted therapies.
A new grant will help increase range of motion for individuals with Duchenne muscular dystrophy by developing an exoskeleton that provides intuitive robotic guidance controls and motorized assistance. The device aims to spare muscle deterioration, keeping people stronger for longer.
Researchers aim to create genetically corrected stem cells to replace the mutated dystrophin gene in Duchenne muscular dystrophy. They plan to use induced pluripotent stem cells to produce healthy muscle progenitor cells, which will repopulate weak muscle mass.
The FDA approved Exondys, a treatment for Duchenne muscular dystrophy, based on data from just 12 patients, raising concerns about scientific evidence and patient advocacy. Families of the boys involved attest to the drug's effectiveness, but critics argue that the agency bowed to pressure rather than making a decision based on evidence.
A study by researchers at Stanford University School of Medicine found that progressively shortening telomeres in heart muscle cells triggered a DNA damage response compromising mitochondrial function. This led to cardiomyopathy and death in mice with Duchenne muscular dystrophy, suggesting new therapeutic targets.
A new investigation finds that vitamin supplements can slow muscle wasting by boosting NAD+ levels in mice. The study supports the potential benefits of NAD+ precursors for patients with muscular dystrophy and other muscle disorders.
Large doses of nicotinamide riboside have been found to effectively counteract the progress of Duchenne muscular dystrophy in animals, reducing muscle inflammation and increasing comfort. The treatment aims to provide worn-out mitochondria with fuel, reversing the disease's damaging effects.
Researchers at Binghamton University found that a genetic polymorphism in the CD40 gene modifies the severity of Duchenne muscular dystrophy, pointing to potential therapeutic approaches. The study suggests that drugs targeting CD40 may improve patient symptoms.
Scientists at the University of Liverpool have discovered a new potential treatment for muscular dystrophy by identifying an enzyme that impairs muscle repair. Elevated levels of elastase, which breaks down connective tissue, were found to impair muscle stem cell function and survival.
A study published in Nature Communications reveals that replacing a protein complex involved in muscle development may alleviate symptoms of muscular dystrophy. The researchers identified a genetic switch that drives pericytes and PICs to become muscle cells, providing a potential target for drug development.
Removing osteopontin from mice with muscular dystrophy reduces inflammation and fibrosis, boosting muscle repair and regeneration. Osteopontin inhibitors may be used to slow disease progression and improve muscle function in DMD patients.
A new study reveals that muscles controlling the eyes and eyelids are selectively spared in Duchenne muscular dystrophy due to higher utrophin levels. Researchers also found ECC machinery and calcium regulation similar to those of quadriceps muscles, challenging current understanding of muscle function.
Researchers at Kobe University have successfully decoded a sugar molecule linked to muscular dystrophy, revealing its role in causing the condition. By identifying the abnormal synthesis of ribitol 5-phosphate, the team uncovered a potential therapeutic target for treating muscular dystrophy.
Researchers at the University of Sheffield discovered that dasatinib can switch off signals in a protein implicated in Duchenne Muscular Dystrophy, leading to a 40% improvement in zebrafish with the condition. The drug has potential as a treatment for slowing muscle deterioration and improving symptoms in patients.
Scientists at UT Southwestern Medical Center successfully stopped the progression of Duchenne muscular dystrophy in young mice using a gene-editing technique. The treatment, delivered via adeno-associated virus 9 (AAV9), corrected the genetic mutation that causes the disease and led to improved muscle structure and function.
A new study has pinpointed the symptoms of rare myotonic dystrophy type 2 (DM2) that are most important to patients. The research, published in Neurology, found that fatigue and pain were key concerns for DM2 patients.
Duchenne muscular dystrophy directly affects muscle stem cells, leading to intrinsic defects in their function. Researchers discovered that dystrophin is a key member of the molecular machinery that enables muscle stem cells sense their orientation in the surrounding tissue.
Researchers have identified the Jagged1 gene as a potential target for therapies to combat Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration. Increasing expression of JAG1 was shown to prevent the development of degenerative disease in zebrafish models.
Researchers have developed new compounds that target three ways to interrupt the disease's pathology in cells, showing promise against myotonic dystrophy type 1. The compounds reduce levels of mutant RNA and reverse symptoms in a fruit fly model.
Researchers have identified a new way to trigger the instructions given by the muscle protein dystrophin, which is found in muscles used for movement and in cardiac muscle cells. The study suggests using drugs that activate AMPK signaling to bypass defective steps in the protein complex pathway.
Researchers successfully treated dogs with Duchenne Muscular Dystrophy using gene therapy, developing a miniature version of the dystrophin protein that protects all muscles. The treatment uses a common virus to deliver the gene, which has shown no symptoms in human bodies and is being planned for human clinical trials.
A study published in PLOS Medicine identified genetic ablation of P2RX7 as a promising approach to treating Duchenne muscular dystrophy, improving muscle structure, strength, and reducing cognitive impairment and bone loss. The findings suggest that P2RX7 antagonists may also reduce certain DMD phenotypes.
A new RNA editing technique called exon skipping has shown promising results in treating a rare and severe form of muscular dystrophy. The treatment, licensed to the Kurt+Peter Foundation, aims to slow down muscle decline and stabilize function in individuals with Limb Girdle Muscular Dystrophy Type 2C.
Researchers from Brigham and Women's Hospital have developed a technique to grow large numbers of muscle cells in the lab, offering a better model for studying muscle diseases like muscular dystrophy. The new method involves mimicking early developmental cues to drive cells to grow into functional muscle fibers.
The American Society of Human Genetics has honored Dr. R. Rodney Howell with the first-ever Advocacy Award for his dedication to leveraging biomedical advances to improve public health. He received the award at ASHG's 65th Annual Meeting in Baltimore.
Researchers found that in muscular dystrophy, abdominal muscles take over more of the respiratory function as diaphragm muscle damage progresses. This study highlights the importance of supporting cardiopulmonary function in neuromuscular disease.
Duke researchers demonstrate a genetic therapeutic technique targeting a large region of the dystrophin gene to treat up to 60 percent of DMD patients. The CRISPR system is used to cut specific exons, altering the gene and producing a shortened dystrophin protein.
A recent study found that approximately 1 in 5,000 young boys in the US have either Duchenne or Becker muscular dystrophy. The disorders affect Hispanic boys more frequently than white or African-American boys. The research team's findings provide valuable information for healthcare professionals to better plan care for affected children.
Researchers developed a video game to measure upper extremity movement in patients with muscular dystrophy, highly correlating scores with daily activities and mobility. The game, using Kinect technology, measures patient performance and can be used across sites internationally.
Researchers have successfully improved muscle repair in mice with muscular dystrophy by increasing the BMI1 gene, leading to increased strength and longer treadmill runs. The study provides a proof of concept for harnessing this gene to enhance muscle regeneration and may lead to new treatments for patients.
A new clinical trial has shown that using available heart failure drugs can slow the progressive decline in heart function in boys with Duchenne muscular dystrophy. The combination of eplerenone and either an ACE inhibitor or angiotensin receptor blocker significantly reduces left ventricular function decline.
Researchers at Cedars-Sinai Medical Center have found that injections of cardiac stem cells may help reverse heart damage caused by Duchenne muscular dystrophy, potentially leading to improved heart function and exercise capacity. The study involved laboratory mice infused with cardiac stem cells, which showed marked improvement in hea...
Researchers developed a method to process ultrasound data in small, handheld instruments that can provide fast and convenient medical information. This technology could enable people with muscular dystrophy to monitor the effectiveness of their medication on a smartphone.
George Dickson receives 'Scientist of the Year' award from the Muscular Dystrophy Campaign for his pioneering work on novel therapies for rare diseases like Duchenne Muscular Dystrophy. The award recognizes his dedication to researching potential treatments and cures for people with DMD and related neuromuscular conditions.
The American Academy of Neurology and the American Association of Neuromuscular & Electrodiagnostic Medicine have developed a new guideline for determining the specific subtype of limb-girdle or distal muscular dystrophy. This guideline is based on a thorough review of available studies and provides recommendations for evaluating sympt...
The new guideline offers direction in evaluating symptoms, family history, ethnicity, physical exams, and lab test results to determine the most suitable genetic tests. It also provides recommendations on treating and managing complications such as muscle wasting, heart problems, and breathing difficulties.
Scientists at USC have developed CALM technology, allowing for high-resolution imaging of single molecules in living animals. The technique revealed that dystrophin regulates calcium channel fluctuations in muscle cells, leading to impaired muscle activity in muscular dystrophy patients.
Researchers discovered that mice missing TRPML1 calcium channel developed similar muscle defects as those present in muscular dystrophy patients. Increasing the activity of this channel improved muscle membrane repair and restored function. The goal is to develop a drug that can activate TRPML1 for potential treatment in humans.
Scientists have pinpointed two new genetic target genes SUN1 and SUN2 that may lead to developing new treatments for Emery-Dreifuss muscular dystrophy, a devastating condition causing muscle wasting and stiffening. The discovery opens up new possibilities for patients with the disease, who currently have no effective treatment options.
Researchers develop a novel approach to synthesize molecules in diseased cells, targeting RNA repeats and demonstrating potent inhibitors for myotonic dystrophy. This breakthrough could lead to highly specific treatments for various debilitating diseases.
A study has restored a missing repair protein in skeletal muscle of patients with muscular dystrophy. Proteasome inhibitors enabled mutated dysferlin proteins to regain function and repair damaged muscle membranes.
Researchers at the University of Missouri School of Medicine have developed a gene therapy that protects mice from a life-threatening heart condition caused by muscular dystrophy. The therapy targets a different gene involved in the heart's response to stress and shows significant improvements in overall heart health.
A study by Cedars-Sinai researchers found that a commonly prescribed drug can restore blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, shortening life expectancy. The results led to a phase III clinical trial for patients with the disease.
Researchers discovered that tadalafil improves blood flow in the muscles of boys with Duchenne muscular dystrophy, allowing for improved exercise performance. The study found that blood flow abnormalities were present even in boys taking corticosteroids, highlighting a potential new therapeutic strategy for treating the disease.
Researchers at Aarhus University discovered that enzyme DDX6 regulates toxic RNA aggregates in muscular dystrophy patients. The study found that increasing DDX6 levels reduces RNA aggregates, while decreasing them leads to more aggregates.
A team of scientists has published a study revealing novel cellular and molecular elements of muscle repair. Researchers found that HDACis drugs create an environment conducive for FAPs to direct muscle regeneration in early stages of Duchenne muscular dystrophy, but fail to work later.
Scientists at WashU Medicine have developed a new approach to treating muscular dystrophy, using nanoparticles loaded with rapamycin to improve recycling of cellular waste. The treatment showed significant improvements in skeletal muscle strength and cardiac function in mice with Duchenne muscular dystrophy.
Researchers from Arizona State University and Stanford Universities have discovered that the key gene Numb plays a role in promoting muscle growth and suppressing Myostatin, which limits muscle growth. The findings provide a new avenue for developing treatments for muscle diseases such as muscular dystrophy and ALS.